Calling All EQA Members!

Elections for Two Seats on the IQN Path Board The Founding Board of IQN Path has now fulfilled its first term of office and we are now looking for expressions of interest from within the EQA scheme membership to become an IQN Path Executive Board Member for the available seats. In order to provide continuity read more…

Article published in The Pathologist

IQN Path, in collaboration with Ventana Medical Systems, have published an article in The Pathologist entitled ‘A Quality Undertaking – Connecting EQA and industry to ensure quality diagnostic testing’. This short article explores the difficulties in standardisation for accuracy and precision in the EQA process and ways that IQN Path is working in collaboration with read more…

IQN Path PD-L1 digital educational resource for EQA

IQN Path is working on setting up a new project to support quality of PDL1 testing. The goal of the project, is to establish a high quality education resource for self-assessment of pathologists on PD-L1 scoring. Digital slides stained with the four different FDA approved tests (from both Agilent and Roche) will be available to view. The digital platform read more…

IQN Path’s Exhibition booth, ECP 2017 Amsterdam

This year IQN Path ASBL had it’s first exhibition booth at the 29th European Congress of Pathology, 2-5th September, 2017 https://www.esp-congress.org. As well as meeting with many IQN Path members, we also had the opportunity to speak with new potential members and also with laboratories looking to join EQA schemes. Many different projects and next read more…

New Publication: Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

IQN Path is pleased to announce the first publication on Liquid Biopsy clinical implementation and quality assessment. Four EQA providers came together under the umbrella of IQN Path ASBL to run a pilot External Quality Assessment scheme for circulating free DNA. This publication “Review of the implementation of plasma ctDNA testing on behalf of IQN Path read more…